scott-effectsofrosiglitazone-2010.pdf (589.75 kB)
Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus
journal contribution
posted on 2010-02-01, 00:00 authored by Juan Molero Navajas, Scott Lee, I Leizerman, A Chajut, Adrian Cooper, Ken WalderKen WalderObjective: To examine the effects of rosiglitazone in intramyocellular lipid (IMCL) content in diabetic Psammomys obesus using novel electron microscopy technologies.
Background: P. obesus is an unique polygenic model of obesity and type 2 diabetes. Male diabetic P. obesus were treated daily with 5 mg/Kg Rosiglitazone by oral gavage for 14 days. Data were compared with a group of age-matched diabetic P. obesus treated with saline vehicle.
Methods: Assessment of insulin resistance and adiposity were determine before and after the treatment period by oral glucose tolerance test (oGTT) and dual energy X-ray absorptiometry (DEXA) analysis. We used a new scanning electron microscopy technology, (WETSEM) to investigate the effects of rosiglitazone administration on IMCL content, size and distribution in red gastrocnemius muscle.
Results: Rosiglitazone treatment improved glucose tolerance in P. obesus with no difference in the overall body fat content although a significant reduction in subscapular fat mass was observed. Rosiglitazone changed the distribution of lipid droplet size in skeletal muscle. Treated animals tended to have smaller lipid droplets compared with saline-treated controls.
Conclusions: Since smaller IMCL droplets are associated with improvements in insulin sensitivity, we propose that this may be an important mechanism by which rosiglitazone affects glucose tolerance.
Background: P. obesus is an unique polygenic model of obesity and type 2 diabetes. Male diabetic P. obesus were treated daily with 5 mg/Kg Rosiglitazone by oral gavage for 14 days. Data were compared with a group of age-matched diabetic P. obesus treated with saline vehicle.
Methods: Assessment of insulin resistance and adiposity were determine before and after the treatment period by oral glucose tolerance test (oGTT) and dual energy X-ray absorptiometry (DEXA) analysis. We used a new scanning electron microscopy technology, (WETSEM) to investigate the effects of rosiglitazone administration on IMCL content, size and distribution in red gastrocnemius muscle.
Results: Rosiglitazone treatment improved glucose tolerance in P. obesus with no difference in the overall body fat content although a significant reduction in subscapular fat mass was observed. Rosiglitazone changed the distribution of lipid droplet size in skeletal muscle. Treated animals tended to have smaller lipid droplets compared with saline-treated controls.
Conclusions: Since smaller IMCL droplets are associated with improvements in insulin sensitivity, we propose that this may be an important mechanism by which rosiglitazone affects glucose tolerance.
History
Journal
B B A - Molecular Basis of DiseaseVolume
1802Issue
2Pagination
235 - 239Publisher
Elsevier BVLocation
Amsterdam, The NetherlandsPublisher DOI
Link to full text
ISSN
0925-4439Language
engPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2010, Elsevier B.V.Usage metrics
Categories
No categories selectedKeywords
Intramyocellular lipidRosiglitazoneThiazolidinedionePsammomys obesusScience & TechnologyLife Sciences & BiomedicineBiochemistry & Molecular BiologyBiophysicsCell BiologySCANNING-ELECTRON-MICROSCOPYMUSCLE TRIGLYCERIDE CONTENTINDUCED INSULIN-RESISTANCETYPE-2 DIABETES-MELLITUSZUCKER FATTY RATSSKELETAL-MUSCLEPPAR-GAMMAGLYCEMIC CONTROLWEIGHT-LOSSIKK-BETA
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC